Could a common heart pill boost cancer therapy? new trial explores propranolol for esophageal cancer
NCT ID NCT04682158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests adding propranolol, a blood pressure medicine, to standard chemoradiation for people with esophageal adenocarcinoma. About 106 participants will receive the combination to see if it is safe and helps control the disease longer. The goal is to improve treatment without increasing side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a swallowed balloon unlock the genetic secrets of esophageal cancer?
- Pulsing radiation may spare esophageal cancer patients from agonizing throat pain
- Personalized radiation pulses could boost esophageal cancer treatment
- Could a dye and camera spare esophageal cancer patients from extensive lymph node removal?
- Which biopsy method best spots early esophageal cancer?
- Can a simple blood test predict leukemia risk after cancer therapy?